Corrigendum to âRandomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)â
Kundranda, M., Gracian, A.C., Zafar, S.F., Meiri, E., Bendell, J., Algül, H., Rivera, F., Ahn, E.R., Watkins, D., Pelzer, U., Charu, V., Zalutskaya, A., Kuesters, G., Pipas, J.M., Santillana, S., AskVolume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.05.011
Date:
August, 2020
File:
PDF, 75 KB
2020